Digene Acquisition Clears Antitrust Waitng Period

From Associated Press:

Qiagen's acquisition of Gaithersburg-based Digene, a maker of gene-based medical tests, has cleared an antitrust waiting period, the companies said today in a statement.

Netherlands-based Qiagen, a diagnostic products maker, agreed to purchase Digene last month in a cash-and-stock deal worth approximately $1.6 billion. The expiration of the antitrust waiting period completes a condition required to close the acquisition.

The transaction is expected to close in August or September, subject to Qiagen shareholder approval and the tender of a majority of Digene's stock before July 20, unless the tender period is extended.

By Mike Shepard  |  July 17, 2007; 11:44 AM ET
Previous: Sallie Mae Profit Up 33 Percent | Next: Fieldstone's Acquisition by N.Y. Firm Is Complete

The comments to this entry are closed.